Study of Docosahexanoic Acid in Patients With Cystic Fibrosis (CF)
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Patients with Cystic Fibrosis have increased oxidative stress and impaired antioxidant
systems. Under certain conditions, docosahexaenoic acid (DHA) intake may have a favorable
role in reducing redox status.
In this randomized, double-blind, cross-over study, DHA (Pro-Mind) and placebo (sunflower
oil) capsules, will be given, daily to 10 patients, 5 mg/kg for 2 weeks then 10 mg/kg for the
next 2 weeks. Biomarkers of lipid peroxidation and vitamin E levels will be measured. Plasma
and platelet lipid compositions will be determined.